
Lecanemab: European drug agency reȷects Alzheimer’s drug amid debate over efficacy and safety
The European Medicines Agency has rejected a marketing authorisation request for the Alzheimer’s disease drug…

The European Medicines Agency has rejected a marketing authorisation request for the Alzheimer’s disease drug…

Doctors should “recommit to maintaining generalist skills” as they specialise so they can “respond to…

Integrated care systems across England must place more priority on tackling dementia or risk the…

The Alzheimer’s disease treatment donanemab leads to a modest slowdown in cognitive decline in the…

In my last column I discussed the lack of detail or meaningful change in the…

Around 40% of dementia cases worldwide could have potentially been delayed or prevented if 12…

Social care is in crisis, with no road map to salvation in sight. Last week…

Ageing and life expectancy are vital issues that need more attention and investment for research,…

One in six people in England has hearing loss—around 42% of people over 50 and…
.jpg)
Practitioners at the interface between the NHS and adult social care can see in plain,…